
Arthur S. Leonard
Examiner (ID: 12301, Phone: (571)270-3073 , Office: P/1633 )
| Most Active Art Unit | 1633 |
| Art Unit(s) | 1631, 1633 |
| Total Applications | 655 |
| Issued Applications | 267 |
| Pending Applications | 112 |
| Abandoned Applications | 289 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18610954
[patent_doc_number] => 20230277684
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => MODIFIED UBE3A GENE FOR A GENE THERAPY APPROACH FOR ANGELMAN SYNDROME
[patent_app_type] => utility
[patent_app_number] => 18/087885
[patent_app_country] => US
[patent_app_date] => 2022-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7658
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 162
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18087885
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/087885 | MODIFIED UBE3A GENE FOR A GENE THERAPY APPROACH FOR ANGELMAN SYNDROME | Dec 22, 2022 | Pending |
Array
(
[id] => 18497703
[patent_doc_number] => 20230220380
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY
[patent_app_type] => utility
[patent_app_number] => 18/065464
[patent_app_country] => US
[patent_app_date] => 2022-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 84157
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18065464
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/065464 | GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY | Dec 12, 2022 | Pending |
Array
(
[id] => 18436376
[patent_doc_number] => 20230183670
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => RNAS FOR WOUND HEALING
[patent_app_type] => utility
[patent_app_number] => 18/056712
[patent_app_country] => US
[patent_app_date] => 2022-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63864
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18056712
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/056712 | RNAS FOR WOUND HEALING | Nov 16, 2022 | Pending |
Array
(
[id] => 18709559
[patent_doc_number] => 20230332179
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => CNS TARGETING AAV VECTORS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/053407
[patent_app_country] => US
[patent_app_date] => 2022-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29289
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18053407
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/053407 | CNS TARGETING AAV VECTORS AND METHODS OF USE THEREOF | Nov 7, 2022 | Pending |
Array
(
[id] => 20480601
[patent_doc_number] => 12529072
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-20
[patent_title] => Transcription modulation in animals using CRISPR/CAS systems
[patent_app_type] => utility
[patent_app_number] => 18/051659
[patent_app_country] => US
[patent_app_date] => 2022-11-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 42
[patent_no_of_words] => 41904
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18051659
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/051659 | Transcription modulation in animals using CRISPR/CAS systems | Oct 31, 2022 | Issued |
Array
(
[id] => 18436458
[patent_doc_number] => 20230183752
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => COMPLEXES FOR GENE DELETION AND EDITING
[patent_app_type] => utility
[patent_app_number] => 18/049724
[patent_app_country] => US
[patent_app_date] => 2022-10-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28249
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18049724
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/049724 | COMPLEXES FOR GENE DELETION AND EDITING | Oct 25, 2022 | Pending |
Array
(
[id] => 18281293
[patent_doc_number] => 20230096765
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-30
[patent_title] => MODIFIED GRAFTS
[patent_app_type] => utility
[patent_app_number] => 17/954674
[patent_app_country] => US
[patent_app_date] => 2022-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15173
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17954674
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/954674 | MODIFIED GRAFTS | Sep 27, 2022 | Pending |
Array
(
[id] => 18596040
[patent_doc_number] => 20230270831
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => METHODS FOR INDUCING SELECTIVE APOPTOSIS
[patent_app_type] => utility
[patent_app_number] => 17/934501
[patent_app_country] => US
[patent_app_date] => 2022-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52773
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17934501
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/934501 | METHODS FOR INDUCING SELECTIVE APOPTOSIS | Sep 21, 2022 | Pending |
Array
(
[id] => 18436392
[patent_doc_number] => 20230183686
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => METHODS FOR MODIFICATION OF TARGET NUCLEIC ACIDS
[patent_app_type] => utility
[patent_app_number] => 17/933005
[patent_app_country] => US
[patent_app_date] => 2022-09-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19306
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17933005
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/933005 | METHODS FOR MODIFICATION OF TARGET NUCLEIC ACIDS | Sep 15, 2022 | Pending |
Array
(
[id] => 18298311
[patent_doc_number] => 20230107997
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-06
[patent_title] => METHODS FOR MODIFICATION OF TARGET NUCLEIC ACIDS
[patent_app_type] => utility
[patent_app_number] => 17/933023
[patent_app_country] => US
[patent_app_date] => 2022-09-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19301
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17933023
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/933023 | METHODS FOR MODIFICATION OF TARGET NUCLEIC ACIDS | Sep 15, 2022 | Pending |
Array
(
[id] => 18306442
[patent_doc_number] => 20230110342
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => COMPOSITIONS AND METHODS OF STIMULATING AND EXPANDING T CELLS
[patent_app_type] => utility
[patent_app_number] => 17/932188
[patent_app_country] => US
[patent_app_date] => 2022-09-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19822
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17932188
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/932188 | COMPOSITIONS AND METHODS OF STIMULATING AND EXPANDING T CELLS | Sep 13, 2022 | Pending |
Array
(
[id] => 18241204
[patent_doc_number] => 20230073515
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-09
[patent_title] => UNIVERSAL DONOR CELLS
[patent_app_type] => utility
[patent_app_number] => 17/818673
[patent_app_country] => US
[patent_app_date] => 2022-08-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44354
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 306
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17818673
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/818673 | UNIVERSAL DONOR CELLS | Aug 8, 2022 | Pending |
Array
(
[id] => 19528579
[patent_doc_number] => 20240352481
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-24
[patent_title] => NFAT-RESPONSIVE REPORTER SYSTEMS FOR ASSESSING CHIMERIC ANTIGEN RECEPTOR ACTIVATION AND METHODS OF MAKING AND USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/292590
[patent_app_country] => US
[patent_app_date] => 2022-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25371
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18292590
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/292590 | NFAT-RESPONSIVE REPORTER SYSTEMS FOR ASSESSING CHIMERIC ANTIGEN RECEPTOR ACTIVATION AND METHODS OF MAKING AND USING THE SAME | Jul 28, 2022 | Pending |
Array
(
[id] => 18351560
[patent_doc_number] => 20230139671
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => OSMOTIC MEDIATED RELEASE SYNTHETIC NANOCARRIERS
[patent_app_type] => utility
[patent_app_number] => 17/815877
[patent_app_country] => US
[patent_app_date] => 2022-07-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18968
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17815877
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/815877 | OSMOTIC MEDIATED RELEASE SYNTHETIC NANOCARRIERS | Jul 27, 2022 | Pending |
Array
(
[id] => 19477526
[patent_doc_number] => 20240325568
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-03
[patent_title] => ENGINEERED TARGETING COMPOSITIONS FOR ENDOTHELIAL CELLS OF THE CENTRAL NERVOUS SYSTEM VASCULATURE AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/580716
[patent_app_country] => US
[patent_app_date] => 2022-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41996
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -39
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18580716
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/580716 | ENGINEERED TARGETING COMPOSITIONS FOR ENDOTHELIAL CELLS OF THE CENTRAL NERVOUS SYSTEM VASCULATURE AND METHODS OF USE THEREOF | Jul 19, 2022 | Pending |
Array
(
[id] => 18183118
[patent_doc_number] => 20230043848
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-09
[patent_title] => Programmable Modification of DNA
[patent_app_type] => utility
[patent_app_number] => 17/865375
[patent_app_country] => US
[patent_app_date] => 2022-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4693
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17865375
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/865375 | Programmable Modification of DNA | Jul 13, 2022 | Pending |
Array
(
[id] => 18145525
[patent_doc_number] => 20230019381
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-19
[patent_title] => NK CELL-BASED THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/850812
[patent_app_country] => US
[patent_app_date] => 2022-06-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21688
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17850812
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/850812 | NK CELL-BASED THERAPY | Jun 26, 2022 | Abandoned |
Array
(
[id] => 17928229
[patent_doc_number] => 20220323354
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-13
[patent_title] => VACCINE FOR ELICITING IMMUNE RESPONSE COMPRISING LIPID NANOPARTICLES AND RNA COMPRISING SEGMENT ENCODING AN IMMUNOGEN
[patent_app_type] => utility
[patent_app_number] => 17/848294
[patent_app_country] => US
[patent_app_date] => 2022-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17080
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 492
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17848294
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/848294 | VACCINE FOR ELICITING IMMUNE RESPONSE COMPRISING LIPID NANOPARTICLES AND RNA COMPRISING SEGMENT ENCODING AN IMMUNOGEN | Jun 22, 2022 | Abandoned |
Array
(
[id] => 18003386
[patent_doc_number] => 20220362152
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-17
[patent_title] => VACCINE FOR ELICITING IMMUNE RESPONSE COMPRISING RNA ENCODING AN IMMUNOGEN AND LIPID FORMULATIONS COMPRISING MOLE PERCENTAGE OF LIPIDS
[patent_app_type] => utility
[patent_app_number] => 17/808519
[patent_app_country] => US
[patent_app_date] => 2022-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15125
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 512
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17808519
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/808519 | Vaccine for eliciting immune response comprising RNA encoding an immunogen and lipid formulations comprising mole percentage of lipids | Jun 22, 2022 | Issued |
Array
(
[id] => 17945773
[patent_doc_number] => 20220332790
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-20
[patent_title] => TRIFUNCTIONAL T CELL-ANTIGEN COUPLER AND METHODS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/808361
[patent_app_country] => US
[patent_app_date] => 2022-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12541
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17808361
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/808361 | TRIFUNCTIONAL T CELL-ANTIGEN COUPLER AND METHODS AND USES THEREOF | Jun 22, 2022 | Pending |